ShareValue scores for CIPLA.NSE: Valuation 58, Quality 68, Growth 39, Health 55.
CIPLA.NSENSE
Cipla Limited
₹1,477.50
(+1.28%)
CIPLA.NSENSE
Cipla Limited
Verdicts
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
Rating
Trap Risk
Return
Company Details
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.